Nebita5 mg

Nebita is indicated for the treatment of hypertension (high blood pressure) in adults, either alone or in combination with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

Off-label / Adjunctive Use

Nebita is also used off-label, based on clinical evidence and specialist practice, as an adjunct in the management of stable, mild-to-moderate chronic heart failure in appropriately selected patients (this is an approved indication in some countries outside the US, but not an FDA-approved indication in the United States). Such use should only be initiated and supervised by a physician experienced in heart failure management.

Each tablet contains Nebivolol (as Nebivolol hydrochloride) as the active ingredient, commonly available in strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. Tablets also contain standard pharmaceutical excipients such as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, and polysorbate 80, which may vary by manufacturer.

Nebita is a highly cardioselective, third-generation beta-1 adrenergic receptor blocker used primarily to treat high blood pressure. It is pharmacologically distinct from older (first- and second-generation) beta-blockers because, in addition to blocking beta-1 receptors in the heart, it also stimulates the release of nitric oxide from vascular endothelium, producing an additional vasodilating effect that helps lower blood pressure and reduce the workload on the heart.

Nebita is administered orally, once daily, and is used long-term as part of the management of chronic hypertension.

Nebita belongs to the class of cardioselective (beta-1 selective) beta-adrenergic blocking agents with vasodilating properties, a subclass of the broader beta-blocker drug class used in cardiovascular medicine.

Nebivolol is a selective antagonist of beta-1 adrenergic receptors at lower doses. Blocking beta-1 receptors in the heart reduces heart rate, myocardial contractility, and cardiac output, and suppresses renin release from the kidneys, all of which contribute to lowering blood pressure.

Unlike older beta-blockers, Nebivolol also has a distinctive secondary mechanism: it promotes endothelial nitric oxide (NO) release, causing peripheral vasodilation. This dual mechanism (beta-1 blockade plus NO-mediated vasodilation) distinguishes it from non-vasodilating beta-blockers such as atenolol or metoprolol and may result in more favorable effects on arterial stiffness and endothelial function.

At higher doses (above the doses typically used for hypertension), cardioselectivity is reduced and beta-2 receptor blockade can occur, which may unmask bronchospasm risk in susceptible individuals. Nebivolol undergoes extensive hepatic metabolism, largely via the CYP2D6 enzyme; metabolism differs between "extensive" and "poor" CYP2D6 metabolizers, which affects drug exposure.

Nebita tablets are taken orally, once daily, with or without food, at approximately the same time each day to maintain consistent blood levels. Tablets should be swallowed with water and not crushed or chewed unless the specific formulation is designed for that (standard tablets should be swallowed whole).

The following are well-established, clinically significant interactions with Nebita:

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, propafenone, quinidine): can significantly increase Nebita blood levels; dose reduction of Nebita may be needed and heart rate should be monitored.
• Other rate- or conduction-slowing agents (verapamil, diltiazem, amiodarone, digoxin, other beta-blockers): concurrent use with Nebita increases the risk of excessive bradycardia, AV block, and hypotension; avoid combination where possible and monitor heart rate/ECG closely if used together.
• Clonidine: Nebita can exacerbate rebound hypertension if clonidine is withdrawn; when discontinuing both drugs, Nebita should be withdrawn several days before clonidine is tapered off.
• Insulin and oral antidiabetic agents: Nebita can mask the tachycardia associated with hypoglycemia; blood glucose monitoring should be reinforced in diabetic patients.
• General anesthetics: may potentiate the cardiodepressant and hypotensive effects of Nebita; anesthesiologists should be informed the patient is taking Nebita.
• NSAIDs: may reduce the antihypertensive effect of Nebita through fluid retention and prostaglandin inhibition.

Most patients tolerate Nebita well. Common side effects (occurring in clinical trials at rates greater than placebo) include:

• Headache
• Fatigue/tiredness
• Dizziness
• Diarrhea and nausea
• Insomnia
• Slow heart rate (bradycardia)
• Shortness of breath (dyspnea)
• Rash
• Peripheral edema (swelling of ankles/feet)

Less common but serious effects can include marked bradycardia, hypotension, heart block, bronchospasm (especially in patients with asthma/COPD), and worsening of peripheral circulation problems. Patients should seek medical attention for fainting, very slow pulse, severe dizziness, or difficulty breathing.

Pregnancy: Data on the use of Nebita in human pregnancy are limited. Animal studies have shown adverse effects (embryo-fetal toxicity) at doses relevant to human exposure. Beta-blockers as a class, when used in the third trimester, can cause neonatal bradycardia, hypotension, and hypoglycemia. Nebita should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close physician supervision.

Lactation: It is not known whether Nebita passes into human breast milk; because of the potential for serious adverse reactions in a nursing infant, breastfeeding is generally not recommended during Nebita therapy unless the treating physician determines the benefit outweighs the risk. A physician should be consulted before use in breastfeeding mothers.

Do Not Stop Abruptly

Nebita must not be discontinued abruptly, particularly in patients with known or suspected coronary artery disease. Sudden withdrawal of beta-blocker therapy can cause a rebound increase in heart rate and blood pressure, and has been associated with worsening angina, myocardial infarction, and ventricular arrhythmias. When stopping Nebita, the dose should be tapered gradually over 1-2 weeks under medical supervision, with the patient monitored during this period, especially if they have ischemic heart disease.

Bronchospastic Disease (Asthma/COPD)

Although Nebita is more cardioselective than older non-selective beta-blockers, cardioselectivity is not absolute and diminishes at higher doses. Patients with bronchospastic disease should generally avoid beta-blockers; if Nebita is used in patients with well-controlled asthma or COPD who have not responded to or cannot tolerate other antihypertensive treatment, it should be used cautiously, at the lowest effective dose, with close monitoring for bronchospasm, and a bronchodilator should be readily available.

Masking of Hypoglycemia

Nebita can mask signs of acute hypoglycemia, such as tachycardia, in patients with diabetes mellitus. Blood glucose should be monitored closely in diabetic patients taking Nebita.

Peripheral Vascular Disease

Beta-blockers, including Nebita, can precipitate or worsen symptoms of arterial insufficiency in patients with peripheral vascular disease (e.g., Raynaud's phenomenon); use with caution and monitor for worsening symptoms.

Anesthesia and Major Surgery

Nebita should generally be continued perioperatively; the anesthesiologist should be informed of Nebita use before surgery due to the risk of additive cardiodepressant effects with certain anesthetic agents.

Thyrotoxicosis

Beta-blockade may mask signs of hyperthyroidism (such as tachycardia); abrupt withdrawal may precipitate a thyroid storm, so Nebita should be tapered carefully in these patients.

Overdose of Nebita may cause severe hypotension, marked bradycardia, cardiac failure, cardiogenic shock, bronchospasm, and hypoglycemia. Any suspected overdose is a medical emergency.

If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt to manage an overdose at home. Hospital-based treatment may include gastric decontamination if presenting early, and supportive measures such as intravenous atropine for bradycardia, IV fluids and vasopressors for hypotension, glucagon for refractory cardiac depression, bronchodilators for bronchospasm, and glucose for hypoglycemia, with continuous cardiac monitoring.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

The safety and efficacy of Nebita in pediatric patients (below 18 years of age) have not been established. Nebita is not recommended for use in children.

Elderly (Geriatric) Use

Nebita has been used in elderly hypertensive patients without a general need for dose adjustment based on age alone, though these patients may be more likely to have reduced renal or hepatic function, so titration should be cautious.

Renal Impairment

See Dosage and Administration for dose adjustment in severe renal impairment.

Hepatic Impairment

Dose adjustment required in moderate hepatic impairment; contraindicated in severe hepatic impairment (see Contraindications).

Pregnancy and Breastfeeding

See Pregnancy and Lactation section.

Nebita is used as a long-term, ongoing treatment for chronic hypertension; it is not a short-course medication. Treatment duration is determined by the prescribing physician based on blood pressure control and cardiovascular risk, and is typically continued indefinitely as part of long-term blood pressure management, with periodic physician review.

Nebivolol is classified as a cardioselective beta-1 adrenergic receptor blocker with vasodilating (nitric-oxide-mediated) properties, part of the broader antihypertensive/cardiovascular drug class of beta-blockers.

Nebivolol works through two complementary mechanisms: (1) selective blockade of beta-1 adrenergic receptors in the heart, which reduces heart rate, cardiac contractility, and renin release, lowering blood pressure; and (2) stimulation of nitric oxide release from vascular endothelial cells, which relaxes blood vessel walls and produces additional vasodilation. This combination distinguishes Nebivolol from older beta-blockers that lack the vasodilating action.

The safety and efficacy of Nebita in children and adolescents under 18 years of age have not been established. Nebita is therefore not recommended for pediatric use, and alternative antihypertensive agents with established pediatric data should be considered by the treating physician.